Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01740297 · ClinicalTrials.gov registry record · Phase 1
Ipilimumab With or Without Talimogene Laherparepvec in Unresected Melanoma
A Phase 1 study, sponsored by Amgen.
- Completed
- Registry status
- Phase 1
- Development phase
- 217
- Enrollment target
NCT01740297 is a Phase 1 study that has completed, run by Amgen. The registered enrollment target is 217 participants.
The verdict
NCT01740297, a Phase 1 study, has completed, sponsored by Amgen.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 217 participants
- Enrollment target
Study Summary
Phase 1b of the study will evaluate the safety of talimogene laherparepvec in combination with ipilimumab. Phase 2 is a randomized study that will evaluate the safety and efficacy of talimogene laherparepvec in combination with ipilimumab versus ipilumumab alone.
Interventions
- DRUG Ipilimumab
- DRUG Talimogene laherparepvec
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 217 participants |
| Start Date | 2013-02-07 |
| Est. Completion | 2021-03-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01740297
The ClinicalTrials.gov registry entry for NCT01740297 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 217 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Amgen, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Ipilimumab is the first listed.
NCT01740297 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01740297 about?
NCT01740297 is a clinical study titled "Ipilimumab With or Without Talimogene Laherparepvec in Unresected Melanoma". Phase 1b of the study will evaluate the safety of talimogene laherparepvec in combination with ipilimumab. Phase 2 is a randomized study that will evaluate the safety and efficacy of talimogene laherparepvec in combination with ipilimumab versus ipilumumab alone.
What is the current status of trial NCT01740297?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 217 participants. The study started on 2013-02-07. Estimated completion is 2021-03-09.
What interventions are being tested in trial NCT01740297?
The interventions under investigation include: Ipilimumab (DRUG), Talimogene laherparepvec (DRUG).
Who is sponsoring clinical trial NCT01740297?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.